Compare Axogen Inc (AXGN) vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axogen Inc vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF — how do they compare? Axogen Inc trades at $38.67 (market cap $2.06B), while State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.52. The key difference: Axogen Inc is trading nearer its 52-week high, State Street SPDR Bloomberg 1-3 Month T-Bill ETF nearer its low. Which is the better fit depends on your goals.
| AXGN | BIL | |
|---|---|---|
Market Cap | $2.06B | — |
Sector | Technology | Fixed Income |
52-Week High | $46.19 | $91.77 |
52-Week Low | $11.28 | $91.27 |
Enterprise Value | $1.98B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
BIL trades at $91.50 with no recent price movement. Technical indicators show a bearish trend, with moving averages signaling sell pressure and oscillators neutral. The ETF maintains consistent dividend payments of $0.27 per share. Market sentiment is influenced by Federal Reserve rate hike speculation and competition among cash ETFs, as noted in recent financial news.
The outlook for BIL hinges on interest rate trends, with potential upside if the Fed hikes rates, boosting short-term Treasury yields. Risks include prolonged low-rate environments and investor shifts to higher-yielding alternatives. Current technical weakness suggests caution, but the ETF's stability and dividends offer defensive appeal in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →
